{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,7,28]],"date-time":"2024-07-28T04:30:15Z","timestamp":1722141015352},"reference-count":37,"publisher":"Bentham Science Publishers Ltd.","issue":"5","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CPD"],"published-print":{"date-parts":[[2019,6,3]]},"abstract":"<jats:sec><jats:title>Background:<\/jats:title><jats:p>Therapeutic tragedies of the past, ethical concerns, and legal risks, among other factors have led to a conservative approach to clinical research during pregnancy, resulting in a de facto exclusion of pregnant women from most clinical therapeutics trials. As a result, there is a deficit of knowledge regarding the safety and proper dosing of medications during pregnancy, leaving prescribers with limited information available to support clinical decision-making. Additionally, there is little development of treatments for pregnancy-specific conditions.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods:<\/jats:title><jats:p>This review describes the current need for therapeutic development in pregnant women, summarizes the history of regulations impacting this research area, and describes current efforts to increase the information used to help make decisions regarding the use of drugs during pregnancy and lactation. This is a brief review of the literature, federal regulations, and policies on research in pregnant women.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results:<\/jats:title><jats:p>While therapeutic development in pregnant women has been limited in the past, recent efforts by academic researchers, bioethicists, industry, advocacy groups, and federal agencies have sought to enhance strategies to increase the participation of pregnant women in clinical research that may benefit them and\/or their fetus.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion:<\/jats:title><jats:p>Collaborative efforts from all stakeholders, including industry, academia, advocacy groups, regulators, and other governmental agencies, if successful will increase the information needed to help make decisions regarding the use of drugs during pregnancy and lactation.<\/jats:p><\/jats:sec>","DOI":"10.2174\/1381612825666190328112202","type":"journal-article","created":{"date-parts":[[2019,6,6]],"date-time":"2019-06-06T04:42:06Z","timestamp":1559796126000},"page":"609-614","update-policy":"http:\/\/dx.doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Collaboration in Regulatory Science to Facilitate Therapeutic Development for Pregnant Women"],"prefix":"10.2174","volume":"25","author":[{"given":"Catherine","family":"Roca","sequence":"first","affiliation":[{"name":"Food and Drug Administration: 10903 New Hampshire Ave, Silver Spring, MD, United States"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leyla","family":"Sahin","sequence":"additional","affiliation":[{"name":"Food and Drug Administration: 10903 New Hampshire Ave, Silver Spring, MD, United States"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lynne","family":"Yao","sequence":"additional","affiliation":[{"name":"Food and Drug Administration: 10903 New Hampshire Ave, Silver Spring, MD, United States"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"965","reference":[{"key":"ref=1","volume":"67","author":"Martin J.A.","year":"2018","unstructured":"Martin JA, Hamilton BE, Osterman MJ, Driscoll AK, Drake P. Births: Final data for 2017.","journal-title":"National Vital Statistics Reports"},{"key":"ref=2","doi-asserted-by":"crossref","first-page":"51.e1","DOI":"10.1016\/j.ajog.2011.02.029","volume":"205","author":"Mitchell A.A.","year":"2011","unstructured":"Mitchell AA, Gilboa SM, Werler MM, Kelley KE, Louik C, Hernandez-Diaz S. National Birth Defects Prevention Study. medication use during pregnancy with particular focus on prescription drugs.","journal-title":"Am J Obstet Gynecol"},{"key":"ref=3","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1111\/1471-0528.14151","volume":"124","author":"Scaffidi J.","year":"2017","unstructured":"Scaffidi J, Mol BW, Keelan JA. The pregnant women as a drug orphan: a global survey of registered clinical trials of pharmacological interventions in pregnancy.","journal-title":"BJOG"},{"key":"ref=4","unstructured":"https:\/\/www.nichd.nih.gov\/ sites\/default\/files\/2018-09\/PRGLAC_Report.pdf"},{"key":"ref=5","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1177\/2168479017696265","volume":"51","author":"Penkov D.","year":"2017","unstructured":"Penkov D, Tomasi P, Eichler I, Murphy D, Yao LP, Temeck J. Pediatric medicine development: an overview and comparison of regulatory processed in the European Union and United States.","journal-title":"Ther Innov Regul Sci"},{"key":"ref=6","unstructured":"https:\/\/www.accessdata.fda.gov\/scripts\/sda\/sdnavigation.cfm? sd=labelingdatabase"},{"key":"ref=7","unstructured":""},{"key":"ref=8","author":"","year":"","unstructured":". Guidance for Industry M3(R2) Nonclinical safety studies for theconduct of human clinical trial and marketing authorization forpharmaceuticals."},{"key":"ref=9","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1016\/j.ajog.2015.05.047","volume":"213","author":"Briggs G.G.","year":"2015","unstructured":"Briggs GG, Polifka JE, Wisner KL. Should pregnant women be included in phase IV clinical drug trials?","journal-title":"Am J Obstet Gynecol"},{"key":"ref=10","doi-asserted-by":"crossref","DOI":"10.3109\/9780203909904","author":"Schardein J.L.","year":"2000","unstructured":"Schardein JL.","journal-title":"Chemically-induced birth defects"},{"key":"ref=11","first-page":"465","volume":"100","author":"Lo W.Y.","year":"2002","unstructured":"Lo WY, Friedman JM. Teratogenicity of recently introduced medications in human pregnancy.","journal-title":"Obstet Gynecol"},{"key":"ref=12","unstructured":"690. e1-11."},{"key":"ref=13","doi-asserted-by":"crossref","first-page":"e1002160","DOI":"10.1371\/journal.pmed.1002160","volume":"13","author":"Pariente G.","year":"2016","unstructured":"Pariente G, Leibson T, Carls A, Adams-Webber T, Ito S, Koren G. Pregnancy-associated changes in pharmacokinetics: a systematic review.","journal-title":"PLoS Med"},{"key":"ref=14","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1007\/s00737-018-0844-z","volume":"21","author":"Mitchell J.","year":"2018","unstructured":"Mitchell J, Goodman J. Comparative effects of antidepressant medications and untreated major depression on pregnancy outcomes: a systematic review.","journal-title":"Arch Women Ment Health"},{"key":"ref=15","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1001\/jama.295.5.499","volume":"295","author":"Cohen L.S.","year":"2006","unstructured":"Cohen LS, Altshuler LL, Harlow BL. Relapse of major depression during pregnancy in women who maintain or discontinue antidepressant treatment.","journal-title":"JAMA"},{"key":"ref=16","doi-asserted-by":"crossref","first-page":"e1002160","DOI":"10.1371\/journal.pmed.1002160","volume":"13","author":"Pariente G.","year":"2016","unstructured":"Pariente G, Leibson T, Carls A, Adams-Webber T, Ito S, Koren G. Pregnancy-associated changes in pharmacokinetics: a systematic review.","journal-title":"PLoS Med"},{"key":"ref=17","first-page":"65","volume":"5","author":"Constantine M.M.","year":"2014","unstructured":"Constantine MM. Physiologic and pharmacokinetic changes in pregnancy.","journal-title":"Front Pharmacol"},{"key":"ref=18","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1038\/sj.clpt.6100126","volume":"81","author":"Andrew M.A.","year":"2007","unstructured":"Andrew MA, Easterling TR, Carr DB. Amoxicillin pharmacokinetics in pregnant women: modeling and simulations of dosage strategies.","journal-title":"Clin Pharmacol Ther"},{"key":"ref=19","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1136\/bmj.2.5296.16","volume":"2","author":"Leck I.M.","year":"1962","unstructured":"Leck IM, Millar ELM. Incidence of malformations since the introduction of thalidomide.","journal-title":"BMJ Med"},{"key":"ref=20","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1056\/NEJMp1210007","volume":"367","author":"Greene J.A.","year":"2012","unstructured":"Greene JA, Podolsky SH. Reform, regulation, and pharmaceuticals--the Kefauver-Harris Amendments at 50.","journal-title":"N Engl J Med"},{"key":"ref=21","unstructured":"https:\/\/www.nytimes.com\/1964\/01\/21\/ archives\/hospital-accused-on-cancer-study-live-cells-given-to-patients.html"},{"key":"ref=22","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1056\/NEJM195802272580901","volume":"258","author":"Ward R.","year":"1958","unstructured":"Ward R, Krugman S, Giles JP, Jacobs AM, Bodansky O. Infectious hepatitis; studies of its natural history and prevention.","journal-title":"N Engl J Med"},{"key":"ref=23","unstructured":"Available from: https:\/\/www.cdc.gov\/tuskegee\/timeline.htm,accessed11\/18\/"},{"key":"ref=24","author":"","year":"","unstructured":". H.R. 7724 An Act to amend the Public Health Service Act."},{"key":"ref=25","unstructured":"https:\/\/www.fda.gov\/downloads\/Drugs\/ GuidanceComplianceRegulatoryInformation\/Guidances\/ UCM071682.pdf"},{"key":"ref=26","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1586\/ecp.11.29","volume":"4","author":"Parekh A.","year":"2011","unstructured":"Parekh A, Fadiran EO, Uhl K, Throckmorton DC. Adverse effects in women: implications for drug development and regulatory policies.","journal-title":"Expert Rev Clin Pharmacol"},{"key":"ref=27","first-page":"39406","volume":"58","author":"","year":"1993","unstructured":". Food and Drug Administration.Guideline for the Study and Evaluation of Gender Differences in the Critical Evaluation of Drugs.","journal-title":"Fed Regist"},{"key":"ref=28","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1097\/00001888-199409000-00003","volume":"69","author":"Pinn V.W.","year":"1994","unstructured":"Pinn VW. The role of NIH Office of Research on Women\u2019s Health.","journal-title":"Acad Med"},{"key":"ref=29","unstructured":""},{"key":"ref=30","first-page":"103","volume":"1","author":"","year":"1993","unstructured":". National Institutes of Health Revitalization Act of 1993. PublicLaw. Congress of the United States of America"},{"key":"ref=31","doi-asserted-by":"crossref","first-page":"5","DOI":"10.3138\/ijfab.1.2.5","volume":"1","author":"Lyerly A.D.","year":"2008","unstructured":"Lyerly AD, Little MO, Faden R. The second wave: Toward responsible inclusion of pregnant women in research.","journal-title":"Int J Fem Approaches Bioeth"},{"key":"ref=32","unstructured":"23-1: E39-45."},{"key":"ref=33","unstructured":"Available from: https:\/\/www.fda.gov\/downloads\/Drugs\/GuidanceComplianceRegulatoryInformation\/Guidances\/UCM071639.pdf"},{"key":"ref=34","author":"","year":"2014 Dec.","unstructured":". Guidance for Industry: Pregnancy, Lactation, and ReproductivePotential: Labeling for Human Prescription Drug and BiologicProducts- Content and Format Food and Drug Administration Centerfor Drug Evaluation and Research"},{"key":"ref=35","unstructured":"https:\/\/www.fda.gov\/ downloads\/Drugs\/GuidanceComplianceRegulatoryInformation\/Guidances\/UCM072133.pdf"},{"key":"ref=36","unstructured":""},{"key":"ref=37","unstructured":""}],"container-title":["Current Pharmaceutical Design"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/eurekaselect.com\/article\/download\/171058","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,12,17]],"date-time":"2020-12-17T06:44:55Z","timestamp":1608187495000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.eurekaselect.com\/171058\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6,3]]},"references-count":37,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2019,6,3]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1381612825666190328112202","relation":{},"ISSN":["1381-6128"],"issn-type":[{"value":"1381-6128","type":"print"}],"subject":[],"published":{"date-parts":[[2019,6,3]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2019-02-25","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-03-22","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-06-03","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}